Accueil Ernstrade Bourse Actualite Stock

Place de cotation: Italian Stock Exchange

Arkimedica S.p.A. is the first Italian managed-care company resulting from the build up process sponsored by the closed end fund Cape Natexis.
The company is led by Simone Cimino and has been listed on the Expandi market of the Italian Stock Exchange since August 1st 2006.
The Arkimedica Group operates in the managed care sector and propose to aggregate a network of successful companies in the health and medical industry. It serves as a reference point for products and services of the health care industry.
The Arkimedica Group is active in the sector of health care and medical products through four synergic divisions: the Contract Division specializing in the turnkey supply of furniture for hospital buildings and nursing homes (Cla Group);
the Care Division operating in the management of assisted nursing homes (Sogespa Group); the Medical Devices Division active in the production and sales of sole-use medical devices (Delta Med Group) and the Equipment Division is in charge of planning, production, and sales of pharmaceutical and hospital sterilization equipment (Icos Group).

Thanks to the diversified but synergic nature of the sectors in which the controlled companies operate, Arkimedica is capable of making the most of the important complementary features of these groups, creating the possibility to widen its own clientele portfolio thanks to long-held contacts of said groups.
Representing more than 30 units of entrepreneur-managers, Arkimedica presents itself as a counterpart for other companies in the sector willing to join the first Italian public company operating in the industry.


Cavriago, April 24th, 2008
Arkimedica S.p.A.:
Important acquisition by Contract Division
Arkimedica announces that it has stipulated, through its subsidiary Cla S.p.A, an agreement to
acquire 70% of Euroclinic Srl, a company based in Castelbolognese (RA) that manufactures and
sells chairs for the otolaryngology, podology, and gynaecology sectors.
Arkimedica forecasts that Euroclinic will achieve a turnover of Euro 4.5 million this year,
approximately 80% of which generated by foreign sales, with an EBITDA of Euro 600,000.
The acquisition price is Euro 2 million, which, considering the company’s net financial position,
envisages an Enterprise Value/EBITDA multiple of approximately 6x.
Maurilio Longo (who will remain a shareholder with 30% of the share capital) will continue to
manage the company, having shown excellent management skills in achieving the company’s
current results in only five years.
Simone Cimino, Arkimedica’s President, says, “I am very pleased with this transaction.
Arkimedica Group’s Contract Division will expand its product range and increase business
synergies among Group companies, especially with regard to foreign sales.”



Copyright 2012